Parkinson Disease (PD) Clinical Trial
Official title:
CODY (Co-design for You): An Immersive Technology Tool for Experiencing and Assessing Home Alterations for Veterans With Movement Disabilities and Disorders
Verified date | January 2020 |
Source | University of Florida |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
CODY (co-design for you) is a Virtual Reality (VR) tool and Application Programming Interface (API) which uses an immersive, interactive environment for using, experiencing and co-designing home alterations. The aim of this research is to assess the efficacy of using CODY to aid and enhance the ability of adults with Parkinson's disease (PD) to experience and choose appropriate home modifications.
Status | Completed |
Enrollment | 39 |
Est. completion date | September 30, 2019 |
Est. primary completion date | September 30, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years to 92 Years |
Eligibility |
Inclusion Criteria: Parkinson's Disease participants - Patients with a mild-to-moderate diagnosis of PD, evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS) and the Modified Hoehn and Yahr stages I-III, by a fellowship trained neurologist, arriving at the diagnosis by applying strict UK Brain Bank criteria - Disease duration is less than 5 years - With phone area code of 352; 904 - Currently on their medications Inclusion Criteria: Healthy participants - Individuals who indicated they would like to be contacted for future research opportunities. - Age-matched (+ or - 5 years) healthy participants without PD - No history of neurological or orthopedic problems that could impair walking function or upper extremity mobility Exclusion Criteria: - Individuals with atypical features of PD, peripheral neuropathy, vestibular dysfunction, and medications affecting balance or alertness/ attention - Individuals with the presence of active unstable medical, diabetes, or any orthopedic conditions - Individuals who have previously undergone any brain surgeries - Individuals who take any anti-psychotic medications - Individuals with dementia as reflected by performance on the Mini-Mental State Examination (MMSE) (score < 24) - Individuals with elevated scores on the Beck Depression Inventory-II (I.E., =20), the recommended cut-off for depressive symptoms in PD by the task force for the Movement Disorders Society or history of severe pre-existing psychiatric difficulties (i.e., schizophrenia) |
Country | Name | City | State |
---|---|---|---|
United States | Shimberg Center for Housing Studies | Gainesville | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Florida |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gait time | Participant will be instructed to walk on a 8' 6" long gait mat and pass through the doorway seen on the headset display. The middle portion of the gait mat with a length of 4' 3" is pressure sensitive and transmits gait time data to the software installed in the encrypted desktop. Gait time is the time between the first heel strike and the last toe off on the mat during the walk is measured as gait time. | Day 1 (3 seconds) | |
Primary | Step time | Participant will be instructed to walk on a 8' 6" long gait mat and pass through the doorway seen on the headset display. The middle portion of the gait mat with a length of 4' 3" is pressure sensitive and transmits step time data to the software installed in the encrypted desktop. Step time is the time to complete one full gait cycle. | Day 1 (0.8 second) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03840252 -
Progression of Striatal and Extrastriatal Degeneration in PD and PSP Patients
|
N/A | |
Withdrawn |
NCT05033912 -
A Study of CST-2032 in Subjects With Cognitive Impairment
|
Phase 1 | |
Completed |
NCT02485600 -
Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients
|
||
Active, not recruiting |
NCT04041193 -
An Innovative Disease-net Management Model for Non-communicable Diseases (SIDERA^B)
|
N/A | |
Recruiting |
NCT05395624 -
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
|
Phase 1/Phase 2 |